Breast Cancer Update
Summary: Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
- Visit Website
- RSS
- Artist: Dr Neil Love
- Copyright: Copyright 2009 Research To Practice. All Rights Reserved
Podcasts:
Outside a protocol setting, carboplatin/docetaxel/trastuzumab followed by trastuzumab for a total duration of one year provides the best potential risk/benefit profile for elderly patients with ER-negative, PR-negative, HER2-positive, multiple node-positive breast cancer with a prior cardiac history.
Outside a protocol setting, a combination of endocrine therapy and trastuzumab provides the best potential risk/benefit profile for women with ER-positive, HER2-positive metastatic disease.
Outside a protocol setting, the combination of lapatinib and capecitabine provides the best potential risk/benefit profile for women with ER-negative, PR-negative, HER2-positive, node-positive disease with cancer recurrence after AC->TH.
Interview with Larry Norton, MD
Interview with Hyman B Muss, MD
Interview with Joseph A Sparano, MD
Roundtable Discussion
Interview with Harold J Burstein, MD, PhD
Interview with Peter M Ravdin, MD, PhD
Interview with Robert Livingston, MD
Interview with Harry D Bear, MD, PhD
Interview with Lisa Carey, MD and Jenny C Chang, MD
Interview with Mark D Pegram, MD
Interview with Victor G Vogel, MD, MHS
Interview with Debu Tripathy, MD
